Navigation Links
Paragon BioTeck, Inc. Announces FDA Approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%
Date:3/22/2013

Tigard, OR (PRWEB) March 22, 2013

Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, to dilate the pupil.

“This approval represents an important milestone not only for Paragon, but also within the eye care community as a whole,” said Patrick Witham, President and CEO of Paragon BioTeck. “Phenylephrine Hydrochloride Ophthalmic Solution has been marketed without FDA approval for decades, and during that time has been administered to millions of patients. With the increase in drug manufacturers domestically and abroad, FDA oversight over drug products is more important than ever. The FDA approval process is in place to ensure both that a drug is safe and that it’s manufactured under appropriate controls and oversight.”

About Phenylephrine Hydrochloride Ophthalmic Solution
Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly a-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial muscle of the iris.

Phenylephrine Hydrochloride Ophthalmic Solution Important Safety Information
Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis, as well as in pediatric patients under the age of one due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. It’s for topical ophthalmic use only, and not for injection.

Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, some fatal, and significant elevations in blood pressure have been reported. Caution is advised in pediatric patients less than five years of age, and in patients with elevated blood pressure, cardiovascular disease or hyperthyroidism. Blood pressure should be monitored in patients with cardiovascular or endocrine disease. Rebound miosis has been reported one day after instillation.

Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision and photophobia. Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage.

About Paragon BioTeck, Inc.
Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight. For more information on the company and its work, visit http://www.paragonbioteck.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10558891.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Price Match Guarantee for Comparable Medical Weight Loss Plans
2. Number One Provider of Hearing Aids in Medford OR, Imaginears, Announces Launch of New Website
3. Sharon Kleyne Announces Investment into Fresh Water IP Technology
4. Manatee Works Announces Second Generation Mobile Decoding Engine
5. Depression Treatment Center.com Announces 2013 Blog Award Winners
6. Cornell Dubilier Announces Long-Life Ultracapacitors
7. MyoNatural Announces New Offer for Chiropractors and Doctors Offices Around the US
8. MinuteHound Announces Time and Attendance Solutions for Fitness Centers and Chains
9. La Jolla Vein Care Announces that Nisha Bunke-Paquette, M.D., FACPh, Inducted As a Fellow Of The American College Of Phlebology
10. NLN Foundation for Nursing Education Announces 2013 Nursing Education Scholarship Program Promoting Academic Progression
11. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Milford, PA (PRWEB) , ... January 24, 2017 ... ... their main product “Lacto-Freedom” was recently accepted as a Registered Trademark by the ... prevent others from using a similar name which could confuse consumers into thinking ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by ... 12th year in 2017. The entrepreneurs will showcase their businesses on February 6, ...
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide ... a distribution partnership with Byers Scientific & Manufacturing , a leading designer, ... the agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The University of ... taken great care to design a program that provides teachers with the specific skills ... This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com is working to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Acidity Regulators Market - ... market for acidity regulators was valued at $4,456 million in 2015, ... a CAGR of 7.96% from 2016 to 2022. Asia-Pacific ... to maintain its lead, followed by North America ...
(Date:1/24/2017)... SAN FRANCISCO , January 24, 2017 ... reach a value of USD 3.8 billion by 2025, ... Inc. The market growth can be attributed to the ... awareness about early diagnosis of micro calcifications in breast ... Cancer Foundation, CDC, and Breast Cancer Organization are promoting ...
(Date:1/24/2017)... For today, Stock-Callers.com scans the following Biotechnology companies: ... Inc. (NASDAQ: ALDR ), BioDelivery Sciences International Inc. ... EGLT ). These equities are part of the Healthcare ... , 2017, with the NYSE Health Care Index dropping about ... 500 also were down 0.3% as a group. These stocks ...
Breaking Medicine Technology: